Latest Breaking News On - Cstone pharmaceuticals - Page 1 : comparemela.com

CStone Pharmaceuticals Unveils Promising CS5001 Data

CStone Pharmaceuticals (HK:2616) has released an update. CStone Pharmaceuticals recently presented promising data from their phase 1a/1b study of C.

CStone's Sugemalimab Poised for European Approval

CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

SUZHOU, China, June 2, 2024 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and…

CStone's CS5001 Shows Promise in Early Trials

CStone Pharmaceuticals (HK:2616) has released an update. CStone Pharmaceuticals has published promising preliminary data from a phase 1a/1b study o.

CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the.